<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332198</url>
  </required_header>
  <id_info>
    <org_study_id>2019_A02882_55</org_study_id>
    <nct_id>NCT04332198</nct_id>
  </id_info>
  <brief_title>Neurobiological and Immunological Mechanisms of Dyspnea in ALS</brief_title>
  <official_title>Neurobiological and Neuro-immunological Mechanisms of Dyspnea in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyspnea; subjective experience of respiratory discomfort; which produces negative emotional&#xD;
      experience, is the most common symptom of patients afflicted with chronic respiratory failure&#xD;
      and its treatments are limited. Amyotrophic Lateral Sclerosis (ALS) related - dyspnea, due to&#xD;
      diaphragmatic dysfunction, is similar to dyspnea during mechanical inspiratory load&#xD;
      (activation of the supplementary motor area, SMA). The perception of pain and dyspnea is&#xD;
      processed in similar brain areas (insula, dorsal anterior cingulate cortex, amygdala and&#xD;
      medial thalamus) and in ALS; relieving dyspnea by noninvasive ventilation (NIV) is associated&#xD;
      with decreased pain thresholds. Otherwise, it is reported systemic elevations of&#xD;
      pro-inflammatory cytokines in chronic pain patients, correlating with intensity of pain, and&#xD;
      during respiratory load in healthy volunteers.&#xD;
&#xD;
      The objectives are to evaluate the cytokines and endorphins rates variations after initiation&#xD;
      of NIV in ALS patients, and to correlate cytokines and endorphins rates with the intensity of&#xD;
      the affective component and the intensity of the sensory component of dyspnea.&#xD;
&#xD;
      The investigators will perform a prospective, experimental study, including 30 ALS patients.&#xD;
      Dyspnea, ventilatory and cardiac settings, electromyographic recording of the scalene muscle&#xD;
      and biological assays (ACTH, endorphin, Neuropeptide P, BDNF, IL1, IL6, IL8, IL10, TNF), will&#xD;
      be measured during spontaneous breathing and during NIV at different times after initiation.&#xD;
&#xD;
      The investigators expect a reduction of immunological and neurobiological markers after&#xD;
      relieving dyspnea by NIV. This work could lead to the development of new treatments for&#xD;
      dyspnea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2022</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the cytokines and endorphins rates variation after initiation of NIV in ALS patients</measure>
    <time_frame>30 minutes</time_frame>
    <description>measure cytokines and endorphins blood levels before and after NIV</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Shortness of Breath</condition>
  <condition>Dyspnea</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>ALS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biological test</intervention_name>
    <description>dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation</description>
    <arm_group_label>ALS patients</arm_group_label>
    <other_name>questionnaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients with chronic respiratory failure with diaphragmatic dysfunction linked to&#xD;
        amyotrophic lateral sclerosis and requiring long-term NIV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other respiratory disease (COPD, asthma, obstructive sleep apnea)&#xD;
&#xD;
          -  Alcohol or psychotropic drug the lasts 24 hours&#xD;
&#xD;
          -  Cognitive impairment&#xD;
&#xD;
          -  Smoking &gt; 10 PA&#xD;
&#xD;
          -  Exacerbation or infection 6 weeks earlier&#xD;
&#xD;
          -  Endstage of illness&#xD;
&#xD;
          -  Chronic or acute pain (VAS &gt; 3)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

